Teachers Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Teachers Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.1M	Buy	60,717 +32,499	+115%	+$499K	﹤0.01%	2250
2018 Q4	$454K	Buy	28,218 +4,750	+20%	+$86.6K	﹤0.01%	2552
2018 Q3	$563K	Buy	+23,468	New	+$537K	﹤0.01%	2582

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Teachers Advisors's RUBY Position: Q1 2019 in Review

Teachers Advisors increased its Rubius Therapeutics, Inc (RUBY) stake by 115% in Q1 2019, buying an estimated $499K and bringing the position to 60,717 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Teachers Advisors first reported a position in RUBY in Q3 2018 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold RUBY as of Q1 2019.

Teachers Advisors held 60,717 shares of Rubius Therapeutics, Inc worth $1.1M as of Q1 2019.
Teachers Advisors bought 32,499 Rubius Therapeutics, Inc shares in Q1 2019, an estimated $499K.
Rubius Therapeutics, Inc made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #2250 holding.
Teachers Advisors first reported a position in Rubius Therapeutics, Inc in Q3 2018 and has held it in 3 quarters since.
67 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.